Gain Therapeutics IncNASDAQ:GANX
- LAST PRICE1.2800
- TODAY'S CHANGE (%)0.0300 (2.4000%)
- Bid / Lots1.2100/ 41
- Ask / Lots1.3100/ 3
- Open / Previous Close1.2000 / 1.2500
- Day Range
- 52 Week Range
- Volume551,544
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GANX |
|---|---|---|
| 09:32 ET | 9233 | 1.22 |
| 09:34 ET | 1200 | 1.21 |
| 09:36 ET | 1100 | 1.21 |
| 09:38 ET | 2200 | 1.22 |
| 09:39 ET | 10893 | 1.22 |
| 09:41 ET | 2600 | 1.21 |
| 09:43 ET | 100 | 1.21 |
| 09:48 ET | 37619 | 1.2537 |
| 09:50 ET | 2100 | 1.27 |
| 09:54 ET | 1000 | 1.26 |
| 09:56 ET | 13191 | 1.25 |
| 09:57 ET | 1909 | 1.24 |
| 10:01 ET | 700 | 1.23 |
| 10:06 ET | 2866 | 1.24 |
| 10:08 ET | 5550 | 1.25 |
| 10:10 ET | 1500 | 1.25 |
| 10:17 ET | 200 | 1.255 |
| 10:19 ET | 780 | 1.255 |
| 10:24 ET | 500 | 1.25 |
| 10:26 ET | 500 | 1.25 |
| 10:33 ET | 989 | 1.25 |
| 10:35 ET | 500 | 1.25 |
| 10:37 ET | 800 | 1.255 |
| 10:39 ET | 5055 | 1.255 |
| 10:50 ET | 1100 | 1.255 |
| 10:51 ET | 6300 | 1.26 |
| 10:53 ET | 200 | 1.2607 |
| 10:57 ET | 10100 | 1.263 |
| 11:00 ET | 200 | 1.26 |
| 11:02 ET | 100 | 1.255 |
| 11:04 ET | 700 | 1.25 |
| 11:11 ET | 740 | 1.2556 |
| 11:15 ET | 700 | 1.25 |
| 11:18 ET | 6108 | 1.25 |
| 11:22 ET | 800 | 1.24 |
| 11:24 ET | 600 | 1.24 |
| 11:26 ET | 300 | 1.24 |
| 11:31 ET | 800 | 1.24 |
| 11:33 ET | 5100 | 1.24 |
| 11:36 ET | 300 | 1.24 |
| 11:38 ET | 300 | 1.24 |
| 11:40 ET | 200 | 1.24 |
| 11:42 ET | 800 | 1.24 |
| 11:44 ET | 100 | 1.245 |
| 11:45 ET | 500 | 1.24 |
| 11:49 ET | 600 | 1.24 |
| 11:51 ET | 600 | 1.24 |
| 11:54 ET | 300 | 1.24 |
| 11:56 ET | 600 | 1.24 |
| 12:00 ET | 400 | 1.24 |
| 12:02 ET | 100 | 1.25 |
| 12:03 ET | 1570 | 1.24 |
| 12:07 ET | 494 | 1.24 |
| 12:14 ET | 1300 | 1.24 |
| 12:18 ET | 500 | 1.24 |
| 12:20 ET | 1308 | 1.2414 |
| 12:21 ET | 49470 | 1.22 |
| 12:23 ET | 600 | 1.21 |
| 12:25 ET | 2300 | 1.22 |
| 12:27 ET | 9265 | 1.235 |
| 12:30 ET | 1000 | 1.235 |
| 12:38 ET | 700 | 1.23 |
| 12:41 ET | 10000 | 1.23 |
| 12:50 ET | 600 | 1.23 |
| 12:54 ET | 500 | 1.2317 |
| 12:56 ET | 5200 | 1.2325 |
| 12:59 ET | 900 | 1.23 |
| 01:08 ET | 500 | 1.23 |
| 01:10 ET | 100 | 1.23 |
| 01:12 ET | 600 | 1.23 |
| 01:19 ET | 1050 | 1.2308 |
| 01:21 ET | 100 | 1.2307 |
| 01:24 ET | 2341 | 1.24 |
| 01:26 ET | 4970 | 1.24 |
| 01:28 ET | 1100 | 1.245 |
| 01:33 ET | 600 | 1.24 |
| 01:35 ET | 800 | 1.24 |
| 01:37 ET | 600 | 1.24 |
| 01:39 ET | 14096 | 1.26 |
| 01:44 ET | 4900 | 1.2506 |
| 01:46 ET | 100 | 1.25 |
| 01:50 ET | 600 | 1.25 |
| 01:51 ET | 17300 | 1.26 |
| 01:53 ET | 18693 | 1.25 |
| 01:55 ET | 1400 | 1.24 |
| 01:57 ET | 900 | 1.24 |
| 02:00 ET | 800 | 1.24 |
| 02:06 ET | 8000 | 1.24 |
| 02:08 ET | 1093 | 1.24 |
| 02:09 ET | 700 | 1.24 |
| 02:11 ET | 500 | 1.244 |
| 02:13 ET | 200 | 1.245 |
| 02:15 ET | 13002 | 1.2499 |
| 02:18 ET | 800 | 1.24 |
| 02:20 ET | 1000 | 1.248 |
| 02:22 ET | 5238 | 1.2525 |
| 02:24 ET | 27000 | 1.255 |
| 02:27 ET | 100 | 1.255 |
| 02:29 ET | 11800 | 1.245 |
| 02:31 ET | 3400 | 1.24 |
| 02:36 ET | 774 | 1.24 |
| 02:38 ET | 2795 | 1.245 |
| 02:40 ET | 2000 | 1.2495 |
| 02:42 ET | 2800 | 1.2499 |
| 02:45 ET | 2600 | 1.24 |
| 02:49 ET | 5000 | 1.245 |
| 02:51 ET | 2600 | 1.24 |
| 02:54 ET | 5012 | 1.245 |
| 02:56 ET | 18775 | 1.245 |
| 02:58 ET | 9000 | 1.2579 |
| 03:00 ET | 3600 | 1.2595 |
| 03:02 ET | 4260 | 1.25 |
| 03:03 ET | 2300 | 1.255 |
| 03:05 ET | 8294 | 1.25 |
| 03:07 ET | 100 | 1.25 |
| 03:09 ET | 300 | 1.25 |
| 03:14 ET | 878 | 1.25 |
| 03:18 ET | 1100 | 1.25 |
| 03:20 ET | 10296 | 1.25 |
| 03:21 ET | 196 | 1.25 |
| 03:23 ET | 548 | 1.25 |
| 03:25 ET | 195 | 1.25 |
| 03:27 ET | 240 | 1.25 |
| 03:30 ET | 1000 | 1.25 |
| 03:32 ET | 1214 | 1.25 |
| 03:34 ET | 430 | 1.25 |
| 03:36 ET | 1308 | 1.2525 |
| 03:38 ET | 1205 | 1.25 |
| 03:39 ET | 6639 | 1.25 |
| 03:41 ET | 300 | 1.25 |
| 03:43 ET | 1030 | 1.255 |
| 03:45 ET | 250 | 1.255 |
| 03:48 ET | 400 | 1.25 |
| 03:50 ET | 410 | 1.25 |
| 03:52 ET | 11640 | 1.255 |
| 03:54 ET | 5600 | 1.27 |
| 03:56 ET | 12149 | 1.27 |
| 03:59 ET | 201 | 1.28 |
Jun 28, 2024
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024, from 4:39PM ET on Friday Jun 28, 2024 by Dow Jones
4:39PM ET on Friday Jun 28, 2024 by Dow Jones
Jun 27, 2024
DJ Gain Therapeutics Appoints Finance Chief Mack to Interim CEO Role, from 4:20PM ET on Thursday Jun 27, 2024 by Dow Jones
4:20PM ET on Thursday Jun 27, 2024 by Dow JonesGain Therapeutics, Inc. Appoints Gene Mack as Interim CEO, from 4:08PM ET on Thursday Jun 27, 2024 by Dow Jones
4:08PM ET on Thursday Jun 27, 2024 by Dow JonesPress Release: Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO, from 4:08PM ET on Thursday Jun 27, 2024 by Dow Jones
4:08PM ET on Thursday Jun 27, 2024 by Dow JonesGain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease, from 8:35AM ET on Thursday Jun 27, 2024 by Dow Jones
8:35AM ET on Thursday Jun 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Gain Therapeutics Inc | 23.1M | -0.8x | --- |
Apollomics Inc | 22.9M | 0.0x | --- |
Biomx Inc | 23.5M | -0.5x | --- |
UNITY Biotechnology Inc | 22.7M | -0.6x | --- |
Biora Therapeutics Inc | 23.7M | -0.1x | --- |
Alterola Biotech Inc | 22.5M | -6.2x | --- |
Company Information
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of GCase function, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
Contact Information
- Headquarters
- 4800 Hampden Lane, Suite 200BETHESDA, MD, United States 20814
- Phone
- 301-500-1556
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Founder
- Khalid Islam
- President, Chief Executive Officer, Director
- Matthias Alder
- Chief Financial Officer, Company Secretary
- Gene Mack
- Director
- Eric Richman
- Independent Director
- Dov Goldstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $23.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 18.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.53 |
Book Value | $0.78 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
